A metabolome analysis of tissues from GBM intracranial implantation mouse models, treated with ketogenic diet and/or the VEGF inhibitor bevacizumab, demonstrates a decrease in aspartic and glutamic acid levels in tumors under ketogenic diet in combination with bevacizumab [67]. This evidence concerns the gene VEGFA and glioblastoma.